|
|
|
| The FDA Guidance on EDDO: What to Know, What to Do | Join Drug Delivery Leader Executive Editor, Fran DeGrazio, as she engages combination product regulatory experts in a candid conversation about the FDA’s recent draft guidance on Essential Drug Delivery Outputs (EDDO). This dynamic discussion will cover aspects such as design verification, control strategies, human factors, and post-approval changes. Registration is free for this digital event. |
|
|
|
|
By Jayet Moon and Arun Mathew | The FDA released a new draft guidance, "Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products," in July. The public comment period closes on Sept. 9, 2024. |
|
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
